• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Policy, Organisation and…
  • Quality of Life

Capturing the Broader Value of Antibiotics

STEDI Roadmap
Read more
  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Innovation for Health System Efficiency and Improvement

Report picture
Read more
  • Drug Development/R&D
  • Value, Affordability, and…
  • Value based pricing

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

6
Read more
  • Antimicrobial Resistance (AMR)
  • Value, Affordability, and…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Proposal for a Novel Antimicrobial  Subscription
Read more
  • Health Care Systems
  • Policy, Organisation and…
  • Economic Evaluation

Reimagining Prevention for a Healthier, More Prosperous Society

Prev web
Read more
  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 17th December 2012

New Research by OHE and University of Glasgow on cost of QALYs in Scotland

New health care technologies often improve health but also increase costs. Judging whether they are good value for money involves comparing what QALYs are gained from new technologies, compared to what QALYs could be gained by using those same resources…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Scotland2-146x150

New health care technologies often improve health but also increase costs. Judging whether they are good value for money involves comparing what QALYs are gained from new technologies, compared to what QALYs could be gained by using those same resources elsewhere in the NHS. This “opportunity cost” is the key consideration behind NICE’s cost effectiveness threshold.

New health care technologies often improve health but also increase costs. Judging whether they are good value for money involves comparing what QALYs are gained from new technologies, compared to what QALYs could be gained by using those same resources elsewhere in the NHS. This “opportunity cost” is the key consideration behind NICE’s cost effectiveness threshold. The value of this threshold is of great importance, especially given the Government’s desire to move towards “value based” pricing of new medicines in the future.

The threshold may be thought of as the incremental cost per QALY gained from the least cost-effective treatment that is currently funded in the NHS. Therefore, one approach to estimating it is to identify services at the margin and their cost-effectiveness.

In collaboration with Dr Andrew Walker of the University of Glasgow, an OHE team comprising Jon Sussex, Sarah Karlsberg Schaffer and Nancy Devlin, has begun research aimed at estimating the cost-per-QALY threshold in the NHS in Scotland. The research uses a previously-untapped source of data on spending at the margin. Funding is being provided by an unrestricted grant from the UK’s American Pharma Group.

Scotland is divided into 14 geographical NHS Boards that are responsible for both the commissioning and provision of health services. In 2010 and 2012, each NHS Board was required to respond to a survey from the Health and Sport Committee of the Scottish Parliament. Boards were asked which incremental service developments they were able to fund at the margin for the coming year. The purpose was to identify planned marginal spending. Another question asked the Boards to list areas where spending has been reduced. Our work will use this information, along with published cost-effectiveness evidence, to quantify the revealed marginal cost per QALY in the NHS in Scotland.

The study also aims to gather information on the factors driving NHS Boards’ expenditure decisions at the margin, and the role of cost-per-QALY evidence in them.

While the data in this study relate specifically to Scotland, the evidence and the conclusions drawn from it will be of interest to the whole of the UK, given the similarities in the funding of the health care systems, the services they provide and the populations they cover.

For more information, contact Jon Sussex at OHE.    

  • Health Care Systems
  • Value, Affordability, and…
  • Grants

Related News

  • News
  • December 2019

New OHE Research Funding: Improving Labour Productivity in Primary Care

Read more
  • News
  • October 2019

Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase

Read more
  • News
  • May 2019

OHE is Leading Research to Develop EQ-5D ‘Bolt-ons’ for Cognition and Vision

Read more
  • News
  • September 2018

UKRI Funds OHE Collaboration in Student Mental Health Research Network

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!